<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no">
    <title>Medical Screening FAQ - LongevityPath</title>
    <link rel="stylesheet" href="brand.css">
    <script src="https://unpkg.com/lucide@latest"></script>
</head>
<body>
    <header class="header">
        <a href="index.html" class="back-btn"><i data-lucide="arrow-left" style="width:20px;height:20px;"></i></a>
        <span class="header-title">Medical Screening FAQ</span>
        <span class="user-badge" id="userBadge"><i data-lucide="user" style="width:12px;height:12px;"></i> <span id="userNameBadge">User</span></span>
    </header>

    <div class="container-evidence">
        <div class="breadcrumb">
            <a href="index.html">LongevityPath</a>
            <span>/</span>
            <a href="index.html">Medical Screening</a>
            <span>/</span>
            Evidence &amp; FAQ
        </div>

        <div class="marketing-cta" id="marketingCta">
            <div class="marketing-cta-title">How Current Are Your Medical Screenings?</div>
            <div class="marketing-cta-text">Take our free assessment to evaluate your compliance with evidence-based screening guidelines for cardiovascular health, cancer prevention, metabolic health, and more.</div>
            <a href="index.html" class="marketing-cta-button">
                <i data-lucide="play" style="width:16px;height:16px;"></i> Start Free Assessment
            </a>
        </div>

                <div class="faq-card" id="score-low">
            <div class="faq-header" onclick="toggleFaq('score-low')">
                <div class="faq-header-content">
                    <h1 class="faq-question-title">I scored below 25% on medical screenings — what am I risking?</h1>
                    <div class="faq-meta">
                        <span>4 min read</span>
                    </div>
                    <div class="faq-preview">Missing recommended screenings allows conditions like hypertension, diabetes, and cancers to develop undetected — but most conditions are treatable when caught early, and screening gaps can be closed quickly...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Missing recommended screenings allows conditions like hypertension, diabetes, and cancers to develop undetected. Many of these conditions are asymptomatic in early stages but treatable when caught early. Your low screening score means you're missing critical opportunities for early intervention — opportunities that literally add years to your life.
                    </div>
                </div>

                <table class="faq-table">
                    <thead>
                        <tr><th>Screening</th><th>Key Finding</th><th>Source</th></tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Blood Pressure</strong></td>
                            <td>Each 20 mmHg rise doubles CVD mortality risk. Early detection enables control that reduces heart attack and stroke risk.</td>
                            <td>Lewington 2002, 1M subjects [<a href="#q-bp">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Colorectal Cancer</strong></td>
                            <td>Colonoscopy reduces CRC mortality by 53% over 23 years. Polypectomy prevents cancer development entirely.</td>
                            <td>Zauber 2012 [<a href="#q-colorectal">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Breast Cancer</strong></td>
                            <td>Mammography reduces breast cancer mortality by 30%. Age-appropriate screening saves lives.</td>
                            <td>Tabár 2011 [<a href="#q-breast">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Cholesterol</strong></td>
                            <td>Each 1 mmol/L LDL reduction reduces major vascular events by 22%. Early intervention prevents disease.</td>
                            <td>CTT 2010, 170K participants [<a href="#q-lipid">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Diabetes</strong></td>
                            <td>Lifestyle intervention reduces diabetes onset by 58% in those with prediabetes. Catch it early and it's reversible.</td>
                            <td>CDC NDPP 2002 [<a href="#q-glucose">details →</a>]</td>
                        </tr>
                    </tbody>
                </table>

                <div class="tip-box">
                    <div class="tip-box-label">The Good News</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Lewington et al. (2002). "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies" The Lancet, 360, 1903-1913. doi:<a href="https://doi.org/10.1016/S0140-6736(02)11911-8" target="_blank">10.1016/S0140-6736(02)11911-8</a></div>
                    <div class="study-ref">[2] Zauber et al. (2012). "Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths" New England Journal of Medicine, 366, 687-696. doi:<a href="https://doi.org/10.1056/NEJMoa1100370" target="_blank">10.1056/NEJMoa1100370</a></div>
                    <div class="study-ref">[3] Tabár et al. (2011). "Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades" Radiology, 260, 658-663. doi:<a href="https://doi.org/10.1148/radiol.11110469" target="_blank">10.1148/radiol.11110469</a></div>
                    <div class="study-ref">[4] CTT Collaboration (2010). "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials" The Lancet, 376, 1670-1681. doi:<a href="https://doi.org/10.1016/S0140-6736(10)61350-5" target="_blank">10.1016/S0140-6736(10)61350-5</a></div>
                    <div class="study-ref">[5] Knowler et al. (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin" New England Journal of Medicine, 346, 393-403. doi:<a href="https://doi.org/10.1056/NEJMoa012512" target="_blank">10.1056/NEJMoa012512</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="score-high">
            <div class="faq-header" onclick="toggleFaq('score-high')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">I scored above 75% — what benefits am I getting from regular screening?</h2>
                    <div class="faq-meta">
                        <span>3 min read</span>
                    </div>
                    <div class="faq-preview">Staying current with recommended screenings means conditions are caught at their earliest, most treatable stage — you're maximizing your chance of early intervention and adding years to your healthspan...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Your high screening score reflects powerful preventive behavior. Staying current with recommended screenings means conditions are caught at their earliest, most treatable stage. You're maximizing your chance of early intervention for cardiovascular disease, cancer, and metabolic disorders — effectively multiplying your years of good health.
                    </div>
                </div>

                <table class="faq-table">
                    <thead>
                        <tr><th>Screening Benefit</th><th>What Your High Score Means</th><th>Source</th></tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Early Detection</strong></td>
                            <td>Conditions caught at stage 1 have vastly better survival rates than advanced stages. Your compliance ensures you're in the best position for intervention.</td>
                            <td>Multiple studies [<a href="#score-low">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Cardiovascular Prevention</strong></td>
                            <td>BP and lipid screening allow preventive medication or lifestyle changes before a heart attack or stroke occurs.</td>
                            <td>Lewington 2002, CTT 2010 [<a href="#q-bp">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Cancer Prevention</strong></td>
                            <td>Screening catches cancers early, or prevents them through polyp removal. Mortality reduction is 20–53% depending on cancer type.</td>
                            <td>Zauber 2012, Tabár 2011 [<a href="#q-colorectal">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Metabolic Health</strong></td>
                            <td>Early diabetes detection enables reversible lifestyle intervention before drug treatment becomes necessary.</td>
                            <td>CDC NDPP 2002 [<a href="#q-glucose">details →</a>]</td>
                        </tr>
                        <tr>
                            <td><strong>Vision &amp; Dental Health</strong></td>
                            <td>Regular eye and dental exams prevent irreversible vision loss and catch oral disease before it impacts systemic health.</td>
                            <td>Tham 2014, Linden 2013 [<a href="#q-eye">details →</a>]</td>
                        </tr>
                    </tbody>
                </table>

                <div class="tip-box">
                    <div class="tip-box-label">Keep It Up</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Lewington et al. (2002). "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies" The Lancet, 360, 1903-1913. doi:<a href="https://doi.org/10.1016/S0140-6736(02)11911-8" target="_blank">10.1016/S0140-6736(02)11911-8</a></div>
                    <div class="study-ref">[2] CTT Collaboration (2010). "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials" The Lancet, 376, 1670-1681. doi:<a href="https://doi.org/10.1016/S0140-6736(10)61350-5" target="_blank">10.1016/S0140-6736(10)61350-5</a></div>
                    <div class="study-ref">[3] Zauber et al. (2012). "Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths" New England Journal of Medicine, 366, 687-696. doi:<a href="https://doi.org/10.1056/NEJMoa1100370" target="_blank">10.1056/NEJMoa1100370</a></div>
                    <div class="study-ref">[4] Tabár et al. (2011). "Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades" Radiology, 260, 658-663. doi:<a href="https://doi.org/10.1148/radiol.11110469" target="_blank">10.1148/radiol.11110469</a></div>
                    <div class="study-ref">[5] Knowler et al. (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin" New England Journal of Medicine, 346, 393-403. doi:<a href="https://doi.org/10.1056/NEJMoa012512" target="_blank">10.1056/NEJMoa012512</a></div>
                    <div class="study-ref">[6] Tham et al. (2014). "Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis" Ophthalmology, 121, 2081-2090. doi:<a href="https://doi.org/10.1016/j.ophtha.2014.05.013" target="_blank">10.1016/j.ophtha.2014.05.013</a></div>
                    <div class="study-ref">[7] Linden et al. (2013). "Periodontal systemic associations: review of the evidence" Journal of Clinical Periodontology, 40, S8-S19. doi:<a href="https://doi.org/10.1111/jcpe.12064" target="_blank">10.1111/jcpe.12064</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-system-de">
            <div class="faq-header" onclick="toggleFaq('q-system-de')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">What does Germany's GKV preventive care cover?</h2>
                    <div class="faq-meta">
                        <span>3 min read</span>
                    </div>
                    <div class="faq-preview">Germany's statutory health insurance (GKV) covers one of the most comprehensive preventive screening programmes in Europe — all at no additional cost to insured members...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Germany's GKV covers <strong>10+ preventive screenings at no cost</strong> to insured members, including the comprehensive Check-up 35 (every 3 years from age 35), skin cancer screening (every 2 years), cancer screenings for cervical, breast, prostate, and colorectal cancers, dental check-ups (twice yearly), and a one-time AAA ultrasound for men at 65. Nearly <strong>90% of Germany's population</strong> (74 million people) is covered under GKV.
                    </div>
                </div>

                <table class="faq-table">
                    <thead>
                        <tr><th>Screening</th><th>Age Start</th><th>Frequency</th></tr>
                    </thead>
                    <tbody>
                        <tr><td><strong>Check-up 35</strong></td><td>35 (once 18–34)</td><td>Every 3 years</td></tr>
                        <tr><td><strong>Skin cancer</strong></td><td>35</td><td>Every 2 years</td></tr>
                        <tr><td><strong>Dental</strong></td><td>18</td><td>Twice yearly</td></tr>
                        <tr><td><strong>Cervical cancer</strong></td><td>20</td><td>Annual / every 3 yr (35+)</td></tr>
                        <tr><td><strong>Breast exam</strong></td><td>30</td><td>Annual palpation</td></tr>
                        <tr><td><strong>Mammography</strong></td><td>50–75</td><td>Every 2 years</td></tr>
                        <tr><td><strong>Prostate exam</strong></td><td>45</td><td>Annual</td></tr>
                        <tr><td><strong>Colorectal</strong></td><td>50</td><td>Stool test / colonoscopy</td></tr>
                        <tr><td><strong>AAA ultrasound</strong></td><td>65 (men)</td><td>Once</td></tr>
                        <tr><td><strong>Eye exam</strong></td><td>40</td><td>Every 2–4 years</td></tr>
                    </tbody>
                </table>

                <p class="prose">
                    
                    The German system is structured around age-triggered entitlements defined in §25 of Social Code Book V. The cornerstone is the <strong>Check-up 35</strong> — a comprehensive health examination covering blood pressure, lipid profile, glucose, kidney function, and hepatitis B/C screening (added in 2020). You can have one check-up between ages 18–34, then every 3 years from 35 onward.
                
                </p>

                <p class="prose">
                    
                    Cancer screenings are generous: skin cancer screening every 2 years from age 35, cervical screening from 20 (Pap annually, then Pap+HPV co-test every 3 years from 35), annual prostate exam from 45, colorectal screening from 50 (stool test or colonoscopy), and mammography every 2 years from 50–75 (recently extended from 69). Most screenings require no referral — you can schedule directly with the specialist.
                
                </p>

                <div class="tip-box">
                    <div class="tip-box-label">How to Access</div>
</div>

            </div>
        </div>
        <div class="faq-card" id="q-system-us">
            <div class="faq-header" onclick="toggleFaq('q-system-us')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">What preventive screenings does the US system recommend?</h2>
                    <div class="faq-meta">
                        <span>3 min read</span>
                    </div>
                    <div class="faq-preview">The US Preventive Services Task Force (USPSTF) issues evidence-graded screening recommendations. Grade A and B screenings must be covered without copay by insurers under the ACA...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        The USPSTF maintains <strong>49 Grade A and B recommendations</strong> for preventive services. Under the Affordable Care Act, insurers must cover these screenings <strong>without copay</strong>. Key screenings include blood pressure (every 2 years from 18), cholesterol (every 4–6 years from 20), diabetes (from 35), mammography (every 2 years from 40), colonoscopy (every 10 years from 45), and lung cancer LDCT (annually for smokers 50–80).
                    </div>
                </div>

                <table class="faq-table">
                    <thead>
                        <tr><th>Screening</th><th>Age Start</th><th>Frequency</th></tr>
                    </thead>
                    <tbody>
                        <tr><td><strong>Blood pressure</strong></td><td>18</td><td>Every 2 years</td></tr>
                        <tr><td><strong>Lipid panel</strong></td><td>20</td><td>Every 4–6 years</td></tr>
                        <tr><td><strong>Diabetes (glucose)</strong></td><td>35</td><td>Every 3 years</td></tr>
                        <tr><td><strong>Cervical cancer</strong></td><td>21</td><td>Pap every 3 yr / HPV every 5 yr</td></tr>
                        <tr><td><strong>Mammography</strong></td><td>40</td><td>Every 2 years</td></tr>
                        <tr><td><strong>Colorectal</strong></td><td>45</td><td>Colonoscopy every 10 yr</td></tr>
                        <tr><td><strong>Lung cancer LDCT</strong></td><td>50 (smokers)</td><td>Annual</td></tr>
                        <tr><td><strong>Prostate (PSA)</strong></td><td>55 (shared decision)</td><td>Every 1–2 years</td></tr>
                        <tr><td><strong>AAA ultrasound</strong></td><td>65 (male smokers)</td><td>Once</td></tr>
                        <tr><td><strong>DEXA bone density</strong></td><td>65 (women)</td><td>Baseline + per provider</td></tr>
                        <tr><td><strong>Skin cancer</strong></td><td>35</td><td>Every 2–3 years</td></tr>
                        <tr><td><strong>Dental</strong></td><td>18</td><td>Every 6–12 months</td></tr>
                        <tr><td><strong>Eye exam</strong></td><td>40</td><td>Every 2–4 years</td></tr>
                    </tbody>
                </table>

                <p class="prose">
                    
                    The US system differs from European models in that there is no single national health service. Instead, the USPSTF — an independent panel of experts — evaluates evidence and assigns letter grades (A through D, plus I for insufficient evidence). Grades A and B are the strongest recommendations, and the ACA mandates that private insurers cover these services with no out-of-pocket cost.
                
                </p>

                <p class="prose">
                    
                    The US approach is notably more aggressive in some areas: mammography starts at 40 (vs 50 in Germany), colorectal screening at 45 (vs 50 in Europe), and lung cancer LDCT screening is established for high-risk smokers. On the other hand, the US lacks a structured general check-up equivalent to Germany's Check-up 35 — preventive services are typically accessed through annual wellness visits coordinated by a primary care physician.
                
                </p>

                <div class="tip-box">
                    <div class="tip-box-label">How to Access</div>
</div>

            </div>
        </div>
        <div class="faq-card" id="q-system-eu">
            <div class="faq-header" onclick="toggleFaq('q-system-eu')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">What does the EU recommend for cancer screening?</h2>
                    <div class="faq-meta">
                        <span>3 min read</span>
                    </div>
                    <div class="faq-preview">The EU Council's 2022 recommendation expanded cancer screening from 3 to 6 cancer types, aiming for 90% coverage by 2025 — but implementation varies significantly between member states...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        The EU Council updated its cancer screening recommendation in December 2022, expanding from 3 cancer types (breast, cervical, colorectal) to <strong>6 types</strong> — adding lung, prostate, and gastric cancer in a stepwise approach. The goal is for <strong>90% of eligible EU citizens</strong> to be offered screening by 2025. Non-cancer screenings (blood pressure, cholesterol, diabetes) are left to individual member states.
                    </div>
                </div>

                <table class="faq-table">
                    <thead>
                        <tr><th>Screening</th><th>EU Recommendation</th><th>Status</th></tr>
                    </thead>
                    <tbody>
                        <tr><td><strong>Breast cancer</strong></td><td>Mammography, women 45–74, every 2 years</td><td>Established</td></tr>
                        <tr><td><strong>Cervical cancer</strong></td><td>HPV test, women 30–65, every 5 years</td><td>Established</td></tr>
                        <tr><td><strong>Colorectal cancer</strong></td><td>FIT test, ages 50–74, every 1–2 years</td><td>Established</td></tr>
                        <tr><td><strong>Lung cancer</strong></td><td>LDCT for high-risk smokers (stepwise)</td><td>Pilot phase</td></tr>
                        <tr><td><strong>Prostate cancer</strong></td><td>Organised screening under research</td><td>Pilot phase</td></tr>
                        <tr><td><strong>Gastric cancer</strong></td><td>H. pylori screen-and-treat in high-incidence areas</td><td>Pilot phase</td></tr>
                    </tbody>
                </table>

                <p class="prose">
                    
                    The EU's screening framework is primarily a cancer-focused recommendation — unlike Germany's GKV or the US USPSTF, it does not cover cardiovascular or metabolic screening at the EU level. Those are delegated to national health systems, which is why the screenings shown for "EU (other)" combine the EU cancer recommendations with common national-level cardiovascular screenings.
                
                </p>

                <p class="prose">
                    
                    The 2022 update was a major expansion of the original 2003 recommendation. For established cancers, the evidence base is strong: mammography from age 45–74 (extended from 50–69), HPV-based cervical screening from 30–65, and colorectal FIT testing from 50–74. For the three new cancers (lung, prostate, gastric), the EU recommends a cautious stepwise rollout — pilot programmes first, then gradual expansion based on real-world outcomes.
                
                </p>

                <div class="warning-box">
                    <div class="warning-box-label">Important: National Variation</div>
</div>

            </div>
        </div>
        <div class="faq-card" id="q-system-other">
            <div class="faq-header" onclick="toggleFaq('q-system-other')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">What screenings are recommended regardless of country?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Regardless of where you live, a core set of screenings — blood pressure, cholesterol, blood glucose, dental, eye, and colorectal — are universally recommended by international consensus...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        If your country's specific guidelines aren't listed, or you're unsure which system applies, we show a <strong>universal baseline of 6 core screenings</strong> recommended by the WHO and international medical consensus: blood pressure, cholesterol, blood glucose, dental check-ups, eye exams, and colorectal cancer screening. These represent the minimum standard that virtually all healthcare systems agree on.
                    </div>
                </div>

                <table class="faq-table">
                    <thead>
                        <tr><th>Screening</th><th>Age Start</th><th>Frequency</th></tr>
                    </thead>
                    <tbody>
                        <tr><td><strong>Blood pressure</strong></td><td>18</td><td>Every 2–3 years</td></tr>
                        <tr><td><strong>Lipid panel</strong></td><td>40</td><td>Every 4–6 years</td></tr>
                        <tr><td><strong>Blood glucose</strong></td><td>40</td><td>Every 3 years</td></tr>
                        <tr><td><strong>Dental</strong></td><td>18</td><td>Every 6–12 months</td></tr>
                        <tr><td><strong>Eye exam</strong></td><td>40</td><td>Every 2–4 years</td></tr>
                        <tr><td><strong>Colorectal</strong></td><td>50</td><td>Per local guidelines</td></tr>
                    </tbody>
                </table>

                <p class="prose">
                    
                    This baseline reflects the common ground across international guidelines. Blood pressure and cholesterol screening are universally recommended because cardiovascular disease is the leading global cause of death. Diabetes screening catches a reversible condition early. Colorectal cancer screening is supported by strong evidence across all populations. Dental and eye exams prevent irreversible damage from conditions that develop silently.
                
                </p>

                <p class="prose">
                    
                    Your country may offer additional screenings beyond this baseline — particularly for breast, cervical, prostate, and skin cancers. We recommend checking with your national health service or primary care physician for the most complete list of entitlements.
                
                </p>

                <div class="tip-box">
                    <div class="tip-box-label">What to Do</div>
</div>

            </div>
        </div>
        <div class="faq-card" id="q-checkup">
            <div class="faq-header" onclick="toggleFaq('q-checkup')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why do regular health check-ups matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">General health checks increase diagnosis of chronic conditions, giving you early opportunities to intervene before conditions progress...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Regular health check-ups increase identification of chronic conditions like hypertension and diabetes. While not shown to reduce mortality directly in all populations, early diagnosis enables treatment that prevents disease progression and complications.
                    </div>
                </div>

                <p class="prose">
                    
                    The key message: check-ups are most valuable for identifying risk factors early, enabling treatment before conditions cause irreversible damage. A baseline visit establishes your normal blood pressure and cholesterol, creating a reference point for future screening.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge review">Cochrane Systematic Review</span>
                        <span class="study-journal">published in Cochrane Database of Systematic Reviews</span>
                    </div>
                    <div class="study-title">General health checks in adults for reducing morbidity and mortality from disease</div>
                    <div class="study-meta">Krogsbøll et al., 2019 · n=252,000 · DOI: 10.1002/14651858.CD009009.pub3</div>
                    <div class="study-finding"><strong>Key finding:</strong> General health checks do NOT reduce all-cause, CV, or cancer mortality; increase diagnoses but not outcomes</div>
                    <a href="https://doi.org/10.1002/14651858.CD009009.pub3" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">What to Expect</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Krogsbøll et al. (2019). "General health checks in adults for reducing morbidity and mortality from disease" Cochrane Database of Systematic Reviews, 2019, CD009009. doi:<a href="https://doi.org/10.1002/14651858.CD009009.pub3" target="_blank">10.1002/14651858.CD009009.pub3</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-bp">
            <div class="faq-header" onclick="toggleFaq('q-bp')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does blood pressure screening matter?</h2>
                    <div class="faq-meta">
                        <span>3 min read</span>
                    </div>
                    <div class="faq-preview">Each 20 mmHg rise in blood pressure doubles CVD death risk. The landmark SPRINT trial showed that intensive BP control reduces heart attacks and mortality by 25–27%...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        A landmark analysis of 61 studies involving 1 million subjects found a continuous risk relationship: each 20 mmHg increase in systolic blood pressure doubles CVD death risk. The landmark SPRINT trial showed that intensive BP control (target 120 vs 140 mmHg) reduced cardiovascular events by 25% and mortality by 27%.
                    </div>
                </div>

                <p class="prose">
                    
                    High blood pressure often has no symptoms — many people with elevated BP feel fine, which is why screening is so important. Regular BP checks allow early intervention before damage to your heart, kidneys, and brain occurs.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge meta-analysis">Meta-analysis</span>
                        <span class="study-journal">published in The Lancet</span>
                    </div>
                    <div class="study-title">Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies</div>
                    <div class="study-meta">Lewington et al., 2002 · n=1,000,000 adults; 12.7M person-years · DOI: 10.1016/S0140-6736(02)11911-8</div>
                    <div class="study-finding"><strong>Key finding:</strong> Each 20 mmHg rise in systolic BP doubles stroke and IHD death rate; continuous relationship down to 115/75 mmHg with no threshold</div>
                    <a href="https://doi.org/10.1016/S0140-6736(02)11911-8" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge rct">Randomized Controlled Trial</span>
                        <span class="study-journal">published in New England Journal of Medicine</span>
                    </div>
                    <div class="study-title">A Randomized Trial of Intensive versus Standard Blood-Pressure Control</div>
                    <div class="study-meta">SPRINT Research Group, 2015 · n=9,361 · DOI: 10.1056/NEJMoa1511939</div>
                    <div class="study-finding"><strong>Key finding:</strong> Intensive BP control (<120 mmHg) reduced CV events by 25% (HR 0.75) and all-cause mortality by 27% (HR 0.73); stopped early for efficacy</div>
                    <a href="https://doi.org/10.1056/NEJMoa1511939" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Action Items</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Lewington et al. (2002). "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies" The Lancet, 360, 1903-1913. doi:<a href="https://doi.org/10.1016/S0140-6736(02)11911-8" target="_blank">10.1016/S0140-6736(02)11911-8</a></div>
                    <div class="study-ref">[2] SPRINT Research Group (2015). "A Randomized Trial of Intensive versus Standard Blood-Pressure Control" New England Journal of Medicine, 373, 2103-2116. doi:<a href="https://doi.org/10.1056/NEJMoa1511939" target="_blank">10.1056/NEJMoa1511939</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-lipid">
            <div class="faq-header" onclick="toggleFaq('q-lipid')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does cholesterol screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Each 1 mmol/L LDL reduction prevents major vascular events in 1 of 50 people annually — screening enables early intervention...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        A meta-analysis of 170,000 participants found that each 1 mmol/L reduction in LDL cholesterol reduces major vascular events by 22%. Screening identifies elevated cholesterol before it causes damage, enabling treatment that reduces heart attack and stroke risk.
                    </div>
                </div>

                <p class="prose">
                    
                    Cholesterol has no symptoms — you cannot feel high cholesterol. This makes screening essential. A simple blood test (lipid panel) measures total cholesterol, LDL, HDL, and triglycerides, enabling risk assessment and early treatment.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge meta-analysis">Meta-analysis</span>
                        <span class="study-journal">published in The Lancet</span>
                    </div>
                    <div class="study-title">Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials</div>
                    <div class="study-meta">CTT Collaboration, 2010 · n=170,000 · DOI: 10.1016/S0140-6736(10)61350-5</div>
                    <div class="study-finding"><strong>Key finding:</strong> Each 1 mmol/L reduction in LDL cholesterol reduces major vascular events by 22% (RR 0.78); no increased cancer or non-vascular mortality</div>
                    <a href="https://doi.org/10.1016/S0140-6736(10)61350-5" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] CTT Collaboration (2010). "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials" The Lancet, 376, 1670-1681. doi:<a href="https://doi.org/10.1016/S0140-6736(10)61350-5" target="_blank">10.1016/S0140-6736(10)61350-5</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-glucose">
            <div class="faq-header" onclick="toggleFaq('q-glucose')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does diabetes screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Lifestyle intervention in prediabetes reduces diabetes onset by 58% — but only if caught early. Screening is your gateway to reversing the disease...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        The Diabetes Prevention Program (DPP) showed that lifestyle intervention in people with prediabetes reduced diabetes incidence by 58%. Screening detects prediabetes before it becomes diabetes — the critical window where intervention is reversible.
                    </div>
                </div>

                <p class="prose">
                    
                    Type 2 diabetes often develops silently, with few symptoms in early stages. By the time symptoms appear, significant damage to blood vessels and nerves may have already occurred. Screening with fasting glucose or HbA1c detects prediabetes when intervention is most effective.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge rct">Randomized Controlled Trial</span>
                        <span class="study-journal">published in New England Journal of Medicine</span>
                    </div>
                    <div class="study-title">Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</div>
                    <div class="study-meta">Knowler et al., 2002 · n=3,234 · DOI: 10.1056/NEJMoa012512</div>
                    <div class="study-finding"><strong>Key finding:</strong> Intensive lifestyle intervention reduced diabetes incidence by 58% (NNT=6.9); metformin reduced by 31% (NNT=13.9); trial stopped early</div>
                    <a href="https://doi.org/10.1056/NEJMoa012512" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Key Message</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Knowler et al. (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin" New England Journal of Medicine, 346, 393-403. doi:<a href="https://doi.org/10.1056/NEJMoa012512" target="_blank">10.1056/NEJMoa012512</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-colorectal">
            <div class="faq-header" onclick="toggleFaq('q-colorectal')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does colorectal cancer screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Colonoscopy reduces colorectal cancer mortality by 53% — and prevents cancer by removing precancerous polyps before they develop...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Colonoscopy with polypectomy (polyp removal) reduced colorectal cancer (CRC) mortality by 53% over 23 years. Unlike most cancer screenings that catch existing disease, colonoscopy actually prevents cancer by removing precancerous polyps before they become malignant.
                    </div>
                </div>

                <p class="prose">
                    
                    Colorectal cancer usually develops over 10+ years from a benign polyp. Screening detects and removes polyps before they become cancer — making this uniquely preventive. Guidelines recommend screening from age 45 (US) or 50 (EU/DE), with repeat colonoscopy every 10 years if normal.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge cohort">Prospective Cohort Study</span>
                        <span class="study-journal">published in New England Journal of Medicine</span>
                    </div>
                    <div class="study-title">Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths</div>
                    <div class="study-meta">Zauber et al., 2012 · n=2,602 · DOI: 10.1056/NEJMoa1100370</div>
                    <div class="study-finding"><strong>Key finding:</strong> Colonoscopic polypectomy reduced CRC mortality by 53% (SIMR 0.47); 12 observed vs 25.4 expected deaths over 23 years</div>
                    <a href="https://doi.org/10.1056/NEJMoa1100370" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Zauber et al. (2012). "Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths" New England Journal of Medicine, 366, 687-696. doi:<a href="https://doi.org/10.1056/NEJMoa1100370" target="_blank">10.1056/NEJMoa1100370</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-breast">
            <div class="faq-header" onclick="toggleFaq('q-breast')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does breast cancer screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Mammography screening reduces breast cancer mortality by 30% — with the largest benefit in younger women and earlier detection...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        A 30-year follow-up study found that mammography screening reduces breast cancer mortality by approximately 30%. Screening detects cancers earlier, when treatment is more effective and outcomes are better.
                    </div>
                </div>

                <p class="prose">
                    
                    Stage at diagnosis is the strongest predictor of breast cancer survival. Screening detects tumors when they're smaller and earlier-stage, greatly improving treatment outcomes. Modern screening combines mammography with supplemental ultrasound when appropriate.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge rct">Cluster RCT</span>
                        <span class="study-journal">published in Radiology</span>
                    </div>
                    <div class="study-title">Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades</div>
                    <div class="study-meta">Tabár et al., 2011 · n=133,065 women · DOI: 10.1148/radiol.11110469</div>
                    <div class="study-finding"><strong>Key finding:</strong> Mammography screening invitation reduced breast cancer mortality by 27-31% (RR 0.69-0.73); NNS 414-519 for 7 years to prevent 1 death</div>
                    <a href="https://doi.org/10.1148/radiol.11110469" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Tabár et al. (2011). "Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades" Radiology, 260, 658-663. doi:<a href="https://doi.org/10.1148/radiol.11110469" target="_blank">10.1148/radiol.11110469</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-cervical">
            <div class="faq-header" onclick="toggleFaq('q-cervical')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does cervical cancer screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Cervical cancer screening (Pap/HPV testing) reduces incidence and mortality by 60–90% — making this one of the most effective cancer prevention tools...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Cervical cancer screening (Pap smear or HPV testing) reduces cervical cancer incidence and mortality by 60–90%. HPV testing is now preferred, starting from age 30–35. Cervical cancer is one of the most preventable cancers when screened regularly.
                    </div>
                </div>

                <p class="prose">
                    
                    Cervical cancer develops over many years from precancerous changes. Screening detects these changes before cancer develops, allowing simple treatment that prevents progression. The shift from Pap smears to HPV testing has further improved detection accuracy.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge review">Systematic Review</span>
                        <span class="study-journal">published in Systematic Reviews</span>
                    </div>
                    <div class="study-title">Screening for cervical cancer: a systematic review and meta-analysis</div>
                    <div class="study-meta">Peirson et al., 2013 · n=Multiple studies · DOI: 10.1186/2046-4053-2-35</div>
                    <div class="study-finding"><strong>Key finding:</strong> Cervical screening reduces incidence and mortality by 60-90%; single lifetime screening reduces mortality RR 0.65</div>
                    <a href="https://doi.org/10.1186/2046-4053-2-35" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Peirson et al. (2013). "Screening for cervical cancer: a systematic review and meta-analysis" Systematic Reviews, 2, 35. doi:<a href="https://doi.org/10.1186/2046-4053-2-35" target="_blank">10.1186/2046-4053-2-35</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-skin">
            <div class="faq-header" onclick="toggleFaq('q-skin')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does skin cancer screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Population-based screening reduced melanoma mortality by 48% in Germany — early detection of skin cancer is highly effective...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        A German population-based screening program reduced melanoma mortality by 48%. Skin cancer, especially melanoma, is highly treatable when caught early — even thin melanomas have excellent survival rates if detected before spreading.
                    </div>
                </div>

                <p class="prose">
                    
                    Melanoma thickness at diagnosis is the strongest predictor of survival. Screening detects melanomas when they're thinner and confined to the skin — giving vastly better outcomes. Basal cell and squamous cell cancers, though common, are even more treatable when caught early.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge ">Population-Based Study</span>
                        <span class="study-journal">published in Journal of the American Academy of Dermatology</span>
                    </div>
                    <div class="study-title">Systematic skin cancer screening in Northern Germany</div>
                    <div class="study-meta">Breitbart et al., 2012 · n=360,288 screened (1.88M eligible) · DOI: 10.1016/j.jaad.2010.11.016</div>
                    <div class="study-finding"><strong>Key finding:</strong> Population-based melanoma screening reduced melanoma mortality by 48% (men 47%, women 49%)</div>
                    <a href="https://doi.org/10.1016/j.jaad.2010.11.016" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Breitbart et al. (2012). "Systematic skin cancer screening in Northern Germany" Journal of the American Academy of Dermatology, 66, 201-211. doi:<a href="https://doi.org/10.1016/j.jaad.2010.11.016" target="_blank">10.1016/j.jaad.2010.11.016</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-prostate">
            <div class="faq-header" onclick="toggleFaq('q-prostate')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why is prostate screening discussed?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">PSA screening reduces prostate cancer mortality by 21% but increases overdiagnosis — shared decision-making with your physician is recommended...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        PSA screening reduces prostate cancer mortality by 21% but identifies many cancers that would never have caused harm (overdiagnosis). Current guidance recommends shared decision-making where you discuss benefits and risks with your physician, rather than routine screening for all men.
                    </div>
                </div>

                <p class="prose">
                    
                    Unlike most cancers, many prostate cancers grow slowly and never cause harm. PSA testing identifies these indolent tumors alongside clinically significant ones, leading to overtreatment. The ERSPC trial found that screening prevented 1 death for every 1,410 men screened.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge rct">Randomized Controlled Trial</span>
                        <span class="study-journal">published in The Lancet</span>
                    </div>
                    <div class="study-title">Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</div>
                    <div class="study-meta">Schröder et al., 2014 · n=182,000 (162,388 core analysis) · DOI: 10.1016/S0140-6736(14)60525-0</div>
                    <div class="study-finding"><strong>Key finding:</strong> PSA screening reduces prostate cancer mortality by 21%; 1 death prevented per 1,410 men screened; substantial overdiagnosis concern</div>
                    <a href="https://doi.org/10.1016/S0140-6736(14)60525-0" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">How to Proceed</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Schröder et al. (2014). "Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up" The Lancet, 384, 2027-2035. doi:<a href="https://doi.org/10.1016/S0140-6736(14)60525-0" target="_blank">10.1016/S0140-6736(14)60525-0</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-aaa">
            <div class="faq-header" onclick="toggleFaq('q-aaa')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does abdominal aortic aneurysm screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">One-time ultrasound screening reduces AAA mortality by 42% — a simple test that finds life-threatening condition before rupture...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        A simple abdominal ultrasound screening reduces AAA-related mortality by 42%. An AAA is a life-threatening condition with no symptoms until rupture — screening detects it early when treatment is safe and effective.
                    </div>
                </div>

                <p class="prose">
                    
                    An abdominal aortic aneurysm (AAA) is an abnormal bulging of the aorta. It often has no symptoms until rupture, which is fatal in ~80% of cases. Screening with ultrasound is non-invasive, inexpensive, and detects AAA while elective repair can prevent rupture.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge rct">Randomized Controlled Trial</span>
                        <span class="study-journal">published in BMJ</span>
                    </div>
                    <div class="study-title">Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study</div>
                    <div class="study-meta">Thompson et al., 2009 · n=67,623 · DOI: 10.1136/bmj.b2307</div>
                    <div class="study-finding"><strong>Key finding:</strong> AAA screening reduces AAA-related mortality by 48% (RR 0.52); 155 AAA deaths in screened vs 296 in control</div>
                    <a href="https://doi.org/10.1136/bmj.b2307" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Thompson et al. (2009). "Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study" BMJ, 338, b2307. doi:<a href="https://doi.org/10.1136/bmj.b2307" target="_blank">10.1136/bmj.b2307</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-dental">
            <div class="faq-header" onclick="toggleFaq('q-dental')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why do regular dental check-ups matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Periodontitis (gum disease) is associated with 14% increased cardiovascular risk — dental health reflects and influences systemic health...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Periodontitis (gum disease) is associated with 14% increased cardiovascular risk. Regular dental exams detect and treat gum disease early, preventing both tooth loss and systemic complications. Oral health is inseparable from overall longevity.
                    </div>
                </div>

                <p class="prose">
                    
                    The mouth is a window to systemic health. Bacteria and inflammatory mediators from gum disease enter the bloodstream, triggering systemic inflammation and atherosclerosis. Regular dental cleaning and early treatment of gum disease reduce both local and systemic disease risk.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge review">Systematic Review</span>
                        <span class="study-journal">published in Journal of Clinical Periodontology</span>
                    </div>
                    <div class="study-title">Periodontal systemic associations: review of the evidence</div>
                    <div class="study-meta">Linden et al., 2013 · n=Multiple studies reviewed · DOI: 10.1111/jcpe.12064</div>
                    <div class="study-finding"><strong>Key finding:</strong> Periodontitis associated with 14-19% increased cardiovascular disease risk; bidirectional relationship suggested</div>
                    <a href="https://doi.org/10.1111/jcpe.12064" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Dental Care Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Linden et al. (2013). "Periodontal systemic associations: review of the evidence" Journal of Clinical Periodontology, 40, S8-S19. doi:<a href="https://doi.org/10.1111/jcpe.12064" target="_blank">10.1111/jcpe.12064</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-eye">
            <div class="faq-header" onclick="toggleFaq('q-eye')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why do eye exams matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Glaucoma affects 76 million people with 50% undiagnosed — early detection prevents irreversible vision loss. Diabetic retinopathy screening prevents blindness...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Glaucoma affects 76 million people worldwide, with 50% undiagnosed. Early detection through eye exams prevents irreversible vision loss. For those with diabetes, regular eye exams detect diabetic retinopathy before it causes blindness.
                    </div>
                </div>

                <p class="prose">
                    
                    Glaucoma often has no early symptoms — it's called "the silent thief of sight" because vision loss develops gradually and unnoticed until significant damage occurs. Regular eye exams measure intraocular pressure and assess optic nerve health, detecting glaucoma before vision loss. For diabetics, retinopathy screening prevents blindness.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge meta-analysis">Systematic Review and Meta-analysis</span>
                        <span class="study-journal">published in Ophthalmology</span>
                    </div>
                    <div class="study-title">Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis</div>
                    <div class="study-meta">Tham et al., 2014 · n=50 studies; 252,894 individuals · DOI: 10.1016/j.ophtha.2014.05.013</div>
                    <div class="study-finding"><strong>Key finding:</strong> Global glaucoma: 76M in 2020, 50% undiagnosed; projected 111.8M by 2040; highest POAG prevalence in Africa (4.2%)</div>
                    <a href="https://doi.org/10.1016/j.ophtha.2014.05.013" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Eye Exam Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Tham et al. (2014). "Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis" Ophthalmology, 121, 2081-2090. doi:<a href="https://doi.org/10.1016/j.ophtha.2014.05.013" target="_blank">10.1016/j.ophtha.2014.05.013</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-lung">
            <div class="faq-header" onclick="toggleFaq('q-lung')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does lung cancer screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Low-dose CT screening reduces lung cancer mortality by 20% in heavy smokers or former smokers — screening is only for high-risk individuals...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Low-dose CT reduced lung cancer mortality by 20% in heavy and former smokers. Screening is only recommended for those with significant smoking history (≥20 pack-years). Non-smokers do not benefit from routine lung cancer screening.
                    </div>
                </div>

                <p class="prose">
                    
                    Lung cancer has poor survival when detected at advanced stages. Screening with low-dose CT detects early-stage cancers with much better treatment outcomes. However, screening is only recommended for those with substantial smoking history — the benefit-risk ratio is favorable only in high-risk groups.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge rct">Randomized Controlled Trial</span>
                        <span class="study-journal">published in New England Journal of Medicine</span>
                    </div>
                    <div class="study-title">Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening</div>
                    <div class="study-meta">NLST Research Team, 2011 · n=53,454 · DOI: 10.1056/NEJMoa1102873</div>
                    <div class="study-finding"><strong>Key finding:</strong> Low-dose CT screening reduces lung cancer mortality by 20% in heavy smokers (247 vs 309 deaths per 100,000 person-years)</div>
                    <a href="https://doi.org/10.1056/NEJMoa1102873" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Eligibility</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] NLST Research Team (2011). "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening" New England Journal of Medicine, 365, 395-409. doi:<a href="https://doi.org/10.1056/NEJMoa1102873" target="_blank">10.1056/NEJMoa1102873</a></div>

                </div>

            </div>
        </div>
        <div class="faq-card" id="q-dexa">
            <div class="faq-header" onclick="toggleFaq('q-dexa')">
                <div class="faq-header-content">
                    <h2 class="faq-question-title">Why does bone density screening matter?</h2>
                    <div class="faq-meta">
                        <span>2 min read</span>
                    </div>
                    <div class="faq-preview">Each standard deviation decrease in bone density increases hip fracture risk 2.6-fold — DEXA screening enables early treatment to prevent fractures...</div>
                </div>
                <i data-lucide="chevron-down" class="faq-toggle" style="width:20px;height:20px;"></i>
            </div>
            <div class="faq-content">
                <div class="quick-answer">
                    <div class="quick-answer-label">Quick Answer</div>
                    <div class="quick-answer-text">
                        Each standard deviation decrease in bone mineral density increases hip fracture risk 2.6-fold. DEXA (bone density) screening identifies osteoporosis before fractures occur, enabling treatment that reduces fracture risk by 40–50% and prevents years of disability.
                    </div>
                </div>

                <p class="prose">
                    
                    Osteoporosis develops silently with no symptoms until a fracture occurs. Hip fractures in older adults often lead to loss of independence and complications. DEXA screening detects low bone density early, enabling medication and lifestyle interventions that reduce fracture risk significantly.
                
                </p>

                <div class="study-citation">
                    <div class="study-header">
                        <span class="study-badge meta-analysis">Meta-analysis</span>
                        <span class="study-journal">published in BMJ</span>
                    </div>
                    <div class="study-title">Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures</div>
                    <div class="study-meta">Marshall et al., 1996 · n=11 cohort studies; ~90,000 person-years · DOI: 10.1136/bmj.312.7041.1254</div>
                    <div class="study-finding"><strong>Key finding:</strong> Each SD decrease in BMD increases fracture risk 1.5-fold (RR 1.5, 95% CI 1.4-1.6); hip fracture risk increases 2.6-fold per SD decrease</div>
                    <a href="https://doi.org/10.1136/bmj.312.7041.1254" target="_blank" class="study-link">View Study</a>
                </div>

                <div class="tip-box">
                    <div class="tip-box-label">Screening Guidelines</div>
</div>

                <div class="study-refs">
                    <div class="study-refs-label">References</div>
                    <div class="study-ref">[1] Marshall et al. (1996). "Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures" BMJ, 312, 1254-1259. doi:<a href="https://doi.org/10.1136/bmj.312.7041.1254" target="_blank">10.1136/bmj.312.7041.1254</a></div>

                </div>

            </div>
        </div>


        <div class="page-footer">
            <p>All recommendations based on peer-reviewed research. Last updated February 2026.</p>
        </div>

        <div class="footer-cta" id="footerCta">
            <div class="footer-cta-text">Ready to assess your screening status?</div>
            <a href="index.html" class="footer-cta-button">
                <i data-lucide="stethoscope" style="width:16px;height:16px;"></i> View Your Medical Screening Score
            </a>
            <div class="footer-cta-meta">Track your preventive health compliance</div>
        </div>
    </div>

    <script>
        lucide.createIcons();

        function toggleFaq(id) {
            const card = document.getElementById(id);
            card.classList.toggle('expanded');
        }

        function openFaqById(id) {
            const card = document.getElementById(id);
            if (card && !card.classList.contains('expanded')) {
                card.classList.add('expanded');
            }
        }

        function handleHashNavigation() {
            if (window.location.hash) {
                const targetId = window.location.hash.substring(1);
                openFaqById(targetId);
                setTimeout(() => {
                    const target = document.getElementById(targetId);
                    if (target) {
                        target.scrollIntoView({ behavior: 'smooth', block: 'start' });
                    }
                }, 100);
            }
        }

        handleHashNavigation();
        window.addEventListener('hashchange', handleHashNavigation);

        

        

        function checkUserStatus() {
            const saved = localStorage.getItem('longevityPathData');
            const marketingCta = document.getElementById('marketingCta');
            const footerCta = document.getElementById('footerCta');
            const userBadge = document.getElementById('userBadge');
            const userNameBadge = document.getElementById('userNameBadge');

            if (saved) {
                const data = JSON.parse(saved);
                userBadge.classList.add('visible');
                userNameBadge.textContent = data.userName || 'User';
                marketingCta.classList.remove('visible');
                footerCta.querySelector('.footer-cta-text').textContent = 'Take control of your longevity. See where you stand.';
                footerCta.querySelector('.footer-cta-button').innerHTML = '<i data-lucide="arrow-left" style="width:16px;height:16px;"></i> Back to Assessment';
                footerCta.querySelector('.footer-cta-meta').textContent = '';
                lucide.createIcons();
            } else {
                marketingCta.classList.add('visible');
                userBadge.classList.remove('visible');
            }
        }

        checkUserStatus();
    </script>
</body>
</html>